Fibroblast-mediated pathways in cardiac hypertrophy

Journal of Molecular and Cellular Cardiology

Volumn 70, Issue , 2014, Pages 64-73

  Fujiu, Katsuhito ^a,b   Nagai, Ryozo ^c,d  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cardiac fibroblast; Cardiac hypertrophy; Fibroblast growth factor signaling; Notch signaling; S100A4; Thrombospondin 1 signaling

Indexed keywords

FIBROBLAST GROWTH FACTOR; NOTCH RECEPTOR; PROTEIN S 100; S100A4 PROTEIN, HUMAN; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; CARDIOMEGALY; CELL COMMUNICATION; FIBROBLAST; GENE EXPRESSION REGULATION; GENETICS; HEART MUSCLE; HEART MUSCLE CELL; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOMEGALY; CELL COMMUNICATION; FIBROBLAST GROWTH FACTORS; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; MYOCARDIUM; MYOCYTES, CARDIAC; RECEPTORS, NOTCH; S100 PROTEINS; SIGNAL TRANSDUCTION; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA;

EID: 84899094818     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.01.013     Document Type: Review

References (145)

1. Banerjee I., Fuseler J.W., Price R.L., Borg T.K., Baudino T.A. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am J Physiol Heart Circ Physiol 2007, 293:H1883-H1891.
2. Vliegen H.W., Van der Laarse A., Cornelisse C.J., Eulderink F. Myocardial changes in pressure overload-induced left ventricular hypertrophy: a study on tissue composition, polyploidization and multinucleation. Eur Heart J 1991, 12:488-494.
3. Fujiu K., Nagai R. Contributions of cardiomyocyte-cardiac fibroblast-immune cell interactions in heart failure development. Basic Res Cardiol 2013, 108:1-15.
4. Heine H.L., Leong H.S., Rossi F.M., McManus B.M., Podor T.J. Strategies of conditional gene expression in myocardium: an overview. Methods Mol Med 2005, 112:109-154.
5. Snider P., Standley K.N., Wang J., Azhar M., Doetschman T., Conway S.J. Origin of cardiac fibroblasts and the role of periostin. Circ Res 2009, 105:934-947.
6. Qian L., Huang Y., Spencer C.I., Foley A., Vedantham V., Liu L., et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012, 485:593-598.
7. Jayawardena T.M., Egemnazarov B., Finch E.A., Zhang L., Payne J.A., Pandya K., et al. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ Res 2012, 110:1465-1473.
8. Acharya A., Baek S.T., Banfi S., Eskiocak B., Tallquist M.D. Efficient inducible Cre-mediated recombination in Tcf21 cell lineages in the heart and kidney. Genesis 2011, 49:870-877.
9. Kong P., Christia P., Saxena A., Su Y., Frangogiannis N.G. Lack of specificity of fibroblast-specific protein 1 in cardiac remodeling and fibrosis. Am J Physiol Heart Circ Physiol 2013, 305:H1363-H1372.
10. Zhou B., Von Gise A., Ma Q., Hu Y.W., Pu W.T. Genetic fate mapping demonstrates contribution of epicardium-derived cells to the annulus fibrosis of the mammalian heart. Dev Biol 2010, 338:251-261.
11. Acharya A., Baek S.T., Huang G., Eskiocak B., Goetsch S., Sung C.Y., et al. The bHLH transcription factor Tcf21 is required for lineage-specific EMT of cardiac fibroblast progenitors. Development 2012, 139:2139-2149.
12. Takeda N., Manabe I., Uchino Y., Eguchi K., Matsumoto S., Nishimura S., et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Invest 2010, 120:254-265.
13. Tian Y., Morrisey E.E. Importance of myocyte-nonmyocyte interactions in cardiac development and disease. Circ Res 2012, 110:1023-1034.
14. Pelliccia A., Maron M.S., Maron B.J. Assessment of left ventricular hypertrophy in a trained athlete: differential diagnosis of physiologic athlete's heart from pathologic hypertrophy. Prog Cardiovasc Dis 2012, 54:387-396.
15. Varnava A.M., Elliott P.M., Mahon N., Davies M.J., McKenna W.J. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol 2001, 88:275-279.
16. Shirani J., Pick R., Roberts W.C., Maron B.J. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000, 35:36-44.
17. Choudhury L., Mahrholdt H., Wagner A., Choi K.M., Elliott M.D., Klocke F.J., et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002, 40:2156-2164.
18. Moon J.C., McKenna W.J., Mccrohon J.A., Elliott P.M., Smith G.C., Pennell D.J. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003, 41:1561-1567.
19. Adabag A.S., Maron B.J., Appelbaum E., Harrigan C.J., Buros J.L., Gibson C.M., et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008, 51:1369-1374.
20. Debold E.P., Schmitt J.P., Patlak J.B., Beck S.E., Moore J.R., Seidman J.G., et al. Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay. Am J Physiol Heart Circ Physiol 2007, 293:H284-H291.
21. Tardiff J.C. Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes. Heart Fail Rev 2005, 10:237-248.
22. Varnava A.M., Elliott P.M., Sharma S., McKenna W.J., Davies M.J. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 2000, 84:476-482.
23. Camici P.G., Crea F. Coronary microvascular dysfunction. N Engl J Med 2007, 356:830-840.
24. Kim J.B., Porreca G.J., Song L., Greenway S.C., Gorham J.M., Church G.M., et al. Polony multiplex analysis of gene expression (pmage) in mouse hypertrophic cardiomyopathy. Science 2007, 316:1481-1484.
25. Ho C.Y., López B., Coelho-Filho O.R., Lakdawala N.K., Cirino A.L., Jarolim P., et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010, 363:552-563.
26. Bogoyevitch M.A., Glennon P.E., Andersson M.B., Clerk A., Lazou A., Marshall C.J., et al. Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes. The potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy. J Biol Chem 1994, 269:1110-1119.
27. Pellieux C., Foletti A., Peduto G., Aubert J.F., Nussberger J., Beermann F., et al. Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J Clin Invest 2001, 108:1843-1851.
28. Santiago J.J., Ma X., Mcnaughton L.J., Nickel B.E., Bestvater B.P., Yu L., et al. Preferential accumulation and export of high molecular weight FGF-2 by rat cardiac non-myocytes. Cardiovasc Res 2011, 89:139-147.
29. Kardami E., Jiang Z.-S., Jimenez S.K., Hirst C.J., Sheikh F., Zahradka P., et al. Fibroblast growth factor 2 isoforms and cardiac hypertrophy. Cardiovasc Res 2004, 63:458-466.
30. Schultz J.E.J., Witt S.A., Nieman M.L., Reiser P.J., Engle S.J., Zhou M., et al. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J Clin Invest 1999, 104:709-719.
31. Jiang Z.-S., Jeyaraman M., Wen G.-B., Fandrich R.R., Dixon I.M.C., Cattini P.A., et al. High- but not low-molecular weight FGF-2 causes cardiac hypertrophy in vivo; possible involvement of cardiotrophin-1. J Mol Cell Cardiol 2007, 42:222-233.
32. Liao S., Bodmer J., Pietras D., Azhar M., Doetschman T., Schultz Jel J. Biological functions of the low and high molecular weight protein isoforms of fibroblast growth factor-2 in cardiovascular development and disease. Dev Dyn 2009, 238:249-264.
33. Peng H., Moffett J., Myers J., Fang X., Stachowiak E.K., Maher P., et al. Novel nuclear signaling pathway mediates activation of fibroblast growth factor-2 gene by type 1 and type 2 angiotensin II receptors. Mol Biol Cell 2001, 12:449-462.
34. Nickel W., Rabouille C. Mechanisms of regulated unconventional protein secretion. Nat Rev Mol Cell Biol 2009, 10:148-155.
35. Hotta Y., Sasaki S., Konishi M., Kinoshita H., Kuwahara K., Nakao K., et al. Fgf16 is required for cardiomyocyte proliferation in the mouse embryonic heart. Dev Dyn 2008, 237:2947-2954.
36. Lu S.Y., Sheikh F., Sheppard P.C., Fresnoza A., Duckworth M.L., Detillieux K.A., et al. FGF-16 is required for embryonic heart development. Biochem Biophys Res Commun 2008, 373:270-274.
37. Fon Tacer K., Bookout A.L., Ding X., Kurosu H., John G.B., Wang L., et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 2010, 24:2050-2064.
38. Matsumoto E., Sasaki S., Kinoshita H., Kito T., Ohta H., Konishi M., et al. Angiotensin II-induced cardiac hypertrophy and fibrosis are promoted in mice lacking Fgf16. Genes Cells 2013, 18:544-553.
39. Lu S.Y., Sontag D.P., Detillieux K.A., Cattini P.A. FGF-16 is released from neonatal cardiac myocytes and alters growth-related signaling: a possible role in postnatal development. Am J Physiol Cell Physiol 2008, 294:C1242-C1249.
40. Bray S.J. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 2006, 7:678-689.
41. High F.A., Epstein J.A. The multifaceted role of Notch in cardiac development and disease. Nat Rev Genet 2008, 9:49-61.
42. Niessen K., Karsan A. Notch signaling in cardiac development. Circ Res 2008, 102:1169-1181.
43. Nemir M., Pedrazzini T. Functional role of Notch signaling in the developing and postnatal heart. J Mol Cell Cardiol 2008, 45:495-504.
44. Rosenblatt-Velin N., Lepore M.G., Cartoni C., Beermann F., Pedrazzini T. FGF-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes. J Clin Invest 2005, 115:1724-1733.
45. Laugwitz K.L., Moretti A., Lam J., Gruber P., Chen Y., Woodard S., et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature 2005, 433:647-653.
46. Beltrami A.P., Barlucchi L., Torella D., Baker M., Limana F., Chimenti S., et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003, 114:763-776.
47. Croquelois A., Domenighetti A.A., Nemir M., Lepore M., Rosenblatt-Velin N., Radtke F., et al. Control of the adaptive response of the heart to stress via the Notch1 receptor pathway. J Exp Med 2008, 205:3173-3185.
48. Gude N.A., Emmanuel G., Wu W., Cottage C.T., Fischer K., Quijada P., et al. Activation of Notch-mediated protective signaling in the myocardium. Circ Res 2008, 102:1025-1035.
49. Kratsios P., Catela C., Salimova E., Huth M., Berno V., Rosenthal N., et al. Distinct roles for cell-autonomous Notch signaling in cardiomyocytes of the embryonic and adult heart. Circ Res 2010, 106:559-572.
50. Russell J.L., Goetsch S.C., Gaiano N.R., Hill J.A., Olson E.N., Schneider J.W. A dynamic Notch injury response activates epicardium and contributes to fibrosis repair. Circ Res 2011, 108:51-59.
51. Nemir M., Metrich M., Plaisance I., Lepore M., Cruchet S., Berthonneche C., et al. The Notch pathway controls fibrotic and regenerative repair in the adult heart. Eur Heart J 2012 Nov 19, in press [Epub ahead of print].
52. Panek A.N., Posch M.G., Alenina N., Ghadge S.K., Erdmann B., Popova E., et al. Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS One 2009, 4:e6743.
53. Hayata N., Fujio Y., Yamamoto Y., Iwakura T., Obana M., Takai M., et al. Connective tissue growth factor induces cardiac hypertrophy through Akt signaling. Biochem Biophys Res Commun 2008, 370:274-278.
54. Berk B.C., Fujiwara K., Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007, 117:568-575.
55. Schellings M.W., Pinto Y.M., Heymans S. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res 2004, 64:24-31.
56. Ribeiro S.M., Poczatek M., Schultz-Cherry S., Villain M., Murphy-Ullrich J.E. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem 1999, 274:13586-13593.
57. Schroen B., Heymans S., Sharma U., Blankesteijn W.M., Pokharel S., Cleutjens J.P.M., et al. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res 2004, 95:515-522.
58. Xia Y., Dobaczewski M., Gonzalez-Quesada C., Chen W., Biernacka A., Li N., et al. Endogenous thrombospondin 1 protects the pressure-overloaded myocardium by modulating fibroblast phenotype and matrix metabolism. Hypertension 2011, 58:902-911.
59. Van Almen G.C., Verhesen W., Van Leeuwen R.E., Van De Vrie M., Eurlings C., Schellings M.W., et al. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell 2011, 10:769-779.
60. Lynch J.M., Maillet M., Vanhoutte D., Schloemer A., Sargent M.A., Blair N.S., et al. A thrombospondin-dependent pathway for a protective ER stress response. Cell 2012, 149:1257-1268.
61. Kikuchi A., Yamamoto H., Sato A., Matsumoto S. New insights into the mechanism of Wnt signaling pathway activation. Int Rev Cell Mol Biol 2011, 291:21-71.
62. Fredriksson R., Lagerstrom M.C., Lundin L.G., Schioth H.B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 2003, 63:1256-1272.
63. Ai Z., Fischer A., Spray D.C., Brown A.M., Fishman G.I. Wnt-1 regulation of connexin43 in cardiac myocytes. J Clin Invest 2000, 105:161-171.
64. Duan J., Gherghe C., Liu D., Hamlett E., Srikantha L., Rodgers L., et al. Wnt1/betacatenin injury response activates the epicardium and cardiac fibroblasts to promote cardiac repair. EMBO J 2012, 31:429-442.
65. Goliasch G., Wiesbauer F., Kastl S.P., Katsaros K.M., Blessberger H., Maurer G., et al. Premature myocardial infarction is associated with low serum levels of Wnt-1. Atherosclerosis 2012, 222:251-256.
66. Aisagbonhi O., Rai M., Ryzhov S., Atria N., Feoktistov I., Hatzopoulos A.K. Experimental myocardial infarction triggers canonical Wnt signaling and endothelial-to-mesenchymal transition. Dis Model Mech 2011, 4:469-483.
67. Laeremans H., Rensen S.S., Ottenheijm H.C., Smits J.F., Blankesteijn W.M. Wnt/frizzled signalling modulates the migration and differentiation of immortalized cardiac fibroblasts. Cardiovasc Res 2010, 87:514-523.
68. Carthy J.M., Garmaroudi F.S., Luo Z., McManus B.M. Wnt3a induces myofibroblast differentiation by upregulating TGF-beta signaling through SMAD2 in a beta-catenin-dependent manner. PLoS One 2011, 6:e19809.
69. Zuo S., Jones W.K., Li H., He Z., Pasha Z., Yang Y., et al. Paracrine effect of Wnt11-overexpressing mesenchymal stem cells on ischemic injury. Stem Cells Dev 2012, 21:598-608.
70. Nagy I.I., Railo A., Rapila R., Hast T., Sormunen R., Tavi P., et al. Wnt-11 signalling controls ventricular myocardium development by patterning N-cadherin and beta-catenin expression. Cardiovasc Res 2010, 85:100-109.
71. Dawson K., Aflaki M., Nattel S. Role of the Wnt-Frizzled system in cardiac pathophysiology: a rapidly developing, poorly understood area with enormous potential. J Physiol 2013, 591:1409-1432.
72. Cingolani O.H. Cardiac hypertrophy and the Wnt/Frizzled pathway. Hypertension 2007, 49:427-428.
73. Blankesteijn W.M., Essers-Janssen Y.P., Ulrich M.M., Smits J.F. Increased expression of a homologue of drosophila tissue polarity gene "frizzled" in left ventricular hypertrophy in the rat, as identified by subtractive hybridization. J Mol Cell Cardiol 1996, 28:1187-1191.
74. Malekar P., Hagenmueller M., Anyanwu A., Buss S., Streit M.R., Weiss C.S., et al. Wnt signaling is critical for maladaptive cardiac hypertrophy and accelerates myocardial remodeling. Hypertension 2010, 55:939-945.
75. Van De Schans V.A.M., Van Den Borne S.W.M., Strzelecka A.E., Janssen B.J.A., Van Der Velden J.L.J., Langen R.C.J., et al. Interruption of Wnt signaling attenuates the onset of pressure overload-induced cardiac hypertrophy. Hypertension 2007, 49:473-480.
76. Morisco C., Zebrowski D., Condorelli G., Tsichlis P., Vatner S.F., Sadoshima J. The Akt-glycogen synthase kinase 3beta pathway regulates transcription of atrial natriuretic factor induced by beta-adrenergic receptor stimulation in cardiac myocytes. J Biol Chem 2000, 275:14466-14475.
77. Haq S., Choukroun G., Kang Z.B., Ranu H., Matsui T., Rosenzweig A., et al. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 2000, 151:117-130.
78. Matsuda T., Zhai P., Maejima Y., Hong C., Gao S., Tian B., et al. Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload. Proc Natl Acad Sci U S A 2008, 105:20900-20905.
79. Haq S., Michael A., Andreucci M., Bhattacharya K., Dotto P., Walters B., et al. Stabilization of beta-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth. Proc Natl Acad Sci U S A 2003, 100:4610-4615.
80. Qu J., Zhou J., Yi X.P., Dong B., Zheng H., Miller L.M., et al. Cardiac-specific haploinsufficiency of beta-catenin attenuates cardiac hypertrophy but enhances fetal gene expression in response to aortic constriction. J Mol Cell Cardiol 2007, 43:319-326.
81. Baurand A., Zelarayan L., Betney R., Gehrke C., Dunger S., Noack C., et al. Beta-catenin downregulation is required for adaptive cardiac remodeling. Circ Res 2007, 100:1353-1362.
82. Diedrichs H., Chi M., Boelck B., Mehlhorn U., Schwinger R.H. Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure. Eur J Heart Fail 2004, 6:3-9.
83. Barandon L., Couffinhal T., Ezan J., Dufourcq P., Costet P., Alzieu P., et al. Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA. Circulation 2003, 108:2282-2289.
84. Akhmetshina A., Palumbo K., Dees C., Bergmann C., Venalis P., Zerr P., et al. Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat Commun 2012, 3:735.
85. Snead A.N., Insel P.A. Defining the cellular repertoire of GPCRs identifies a profibrotic role for the most highly expressed receptor, protease-activated receptor 1, in cardiac fibroblasts. FASEB J 2012, 26:4540-4547.
86. Matallanas D., Romano D., Hamilton G., Kolch W., O'Neill E. A Hippo in the ointment: MST signalling beyond the fly. Cell Cycle 2008, 7:879-884.
87. Heallen T., Zhang M., Wang J., Bonilla-Claudio M., Klysik E., Johnson R.L., et al. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 2011, 332:458-461.
88. Xin M., Kim Y., Sutherland L.B., Qi X., McAnally J., Schwartz R.J., et al. Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size. Sci Signal 2011, 4:ra70.
89. Xin M., Kim Y., Sutherland L.B., Murakami M., Qi X., McAnally J., et al. Hippo pathway effector Yap promotes cardiac regeneration. Proc Natl Acad Sci U S A 2013, 110:13839-13844.
90. Odashima M., Usui S., Takagi H., Hong C., Liu J., Yokota M., et al. Inhibition of endogenous Mst1 prevents apoptosis and cardiac dysfunction without affecting cardiac hypertrophy after myocardial infarction. Circ Res 2007, 100:1344-1352.
91. Yamamoto S., Yang G., Zablocki D., Liu J., Hong C., Kim S.J., et al. Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. J Clin Invest 2003, 111:1463-1474.
92. Matsui Y., Nakano N., Shao D., Gao S., Luo W., Hong C., et al. Lats2 is a negative regulator of myocyte size in the heart. Circ Res 2008, 103:1309-1318.
93. Tommasi S., Dammann R., Zhang Z., Wang Y., Liu L., Tsark W.M., et al. Tumor susceptibility of Rassf1a knockout mice. Cancer Res 2005, 65:92-98.
94. Del Re D.P., Matsuda T., Zhai P., Gao S., Clark G.J., Van Der Weyden L., et al. Proapoptotic Rassf1A/Mst1 signaling in cardiac fibroblasts is protective against pressure overload in mice. J Clin Invest 2010, 120:3555-3567.
95. Gibbs F.E., Barraclough R., Platt-Higgins A., Rudland P.S., Wilkinson M.C., Parry E.W. Immunocytochemical distribution of the calcium-binding protein p9Ka in normal rat tissues: variation in the cellular location in different tissues. J Histochem Cytochem 1995, 43:169-180.
96. Watanabe Y., Kobayashi R., Ishikawa T., Hidaka H. Isolation and characterization of a calcium-binding protein derived from mRNA termed p9Ka, pEL-98, 18A2, or 42A by the newly synthesized vasorelaxant W-66 affinity chromatography. Arch Biochem Biophys 1992, 292:563-569.
97. Schmidt-Hansen B., Klingelhöfer J., Grum-Schwensen B., Christensen A., Andresen S., Kruse C., et al. Functional significance of metastasis-inducing S100A4 (Mts1) in tumor-stroma interplay. J Biol Chem 2004, 279:24498-24504.
98. Garrett S.C., Varney K.M., Weber D.J., Bresnick A.R. S100A4, a mediator of metastasis. J Biol Chem 2006, 281:677-680.
99. Greenway S., Van Suylen R.J., Du Marchie Sarvaas G., Kwan E., Ambartsumian N., Lukanidin E., et al. S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am J Pathol 2004, 164:253-262.
100. Brisset A.C., Hao H., Camenzind E., Bacchetta M., Geinoz A., Sanchez J.-C., et al. Intimal smooth muscle cells of porcine and human coronary artery express S100A4, a marker of the rhomboid phenotype in vitro. Circ Res 2007, 100:1055-1062.
101. Iwano M., Plieth D., Danoff T.M., Xue C., Okada H., Neilson E.G. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002, 110:341-350.
102. Grigorian M., Andresen S., Tulchinsky E., Kriajevska M., Carlberg C., Kruse C., et al. Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction. J Biol Chem 2001, 276:22699-22708.
103. Schneider M., Kostin S., Strøm C.C., Aplin M., Lyngbæk S., Theilade J., et al. S100A4 is upregulated in injured myocardium and promotes growth and survival of cardiac myocytes. Cardiovasc Res 2007, 75:40-50.
104. Tamaki Y., Iwanaga Y., Niizuma S., Kawashima T., Kato T., Inuzuka Y., et al. Metastasis-associated protein, S100A4 mediates cardiac fibrosis potentially through the modulation of p53 in cardiac fibroblasts. J Mol Cell Cardiol 2013, 57:72-81.
105. Fujiu K., Manabe I., Nagai R. Renal collecting duct epithelial cells regulate inflammation in tubulointerstitial damage in mice. J Clin Invest 2011, 121:3425-3441.
106. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
107. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
108. Fraccarollo D., Galuppo P., Hildemann S., Christ M., Ertl G., Bauersachs J. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 2003, 42:1666-1673.
109. Kuster G.M., Kotlyar E., Rude M.K., Siwik D.A., Liao R., Colucci W.S., et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 2005, 111:420-427.
110. Lother A., Berger S., Gilsbach R., Rösner S., Ecke A., Barreto F., et al. Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension 2011, 57:746-754.
111. Usher M.G., Duan S.Z., Ivaschenko C.Y., Frieler R.A., Berger S., Schutz G., et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 2010, 120:3350-3364.
112. Rickard A.J., Morgan J., Tesch G., Funder J.W., Fuller P.J., Young M.J. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 2009, 54:537-543.
113. Mccurley A., Pires P.W., Bender S.B., Aronovitz M., Zhao M.J., Metzger D., et al. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 2012, 18:1429-1433.
114. Weeks K.L., Mcmullen J.R. The athlete's heart vs. the failing heart: can signaling explain the two distinct outcomes?. Physiology (Bethesda) 2011, 26:97-105.
115. Zafeiridis A., Jeevanandam V., Houser S.R., Margulies K.B. Regression of cellular hypertrophy after left ventricular assist device support. Circulation 1998, 98:656-662.
116. Ogletree-Hughes M.L., Stull L.B., Sweet W.E., Smedira N.G., McCarthy P.M., Moravec C.S. Mechanical unloading restores beta-adrenergic responsiveness and reverses receptor downregulation in the failing human heart. Circulation 2001, 104:881-886.
117. Dipla K., Mattiello J.A., Jeevanandam V., Houser S.R., Margulies K.B. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation 1998, 97:2316-2322.
118. Hudlicka O., Brown M., Egginton S. Angiogenesis in skeletal and cardiac muscle. Physiol Rev 1992, 72:369-417.
119. Shiojima I., Sato K., Izumiya Y., Schiekofer S., Ito M., Liao R., et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005, 115:2108-2118.
120. Jiang Y., Reynolds C., Xiao C., Feng W., Zhou Z., Rodriguez W., et al. Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice. J Exp Med 2007, 204:657-666.
121. Zuo X., Xie H., Dong D., Jiang N., Zhu H., Kang Y.J. Cytochrome c oxidase is essential for copper-induced regression of cardiomyocyte hypertrophy. Cardiovasc Toxicol 2010, 10:208-215.
122. Zhou Y., Bourcy K., Kang Y.J. Copper-induced regression of cardiomyocyte hypertrophy is associated with enhanced vascular endothelial growth factor receptor-1 signalling pathway. Cardiovasc Res 2009, 84:54-63.
123. Zhou Y., Jiang Y., Kang Y.J. Copper reverses cardiomyocyte hypertrophy through vascular endothelial growth factor-mediated reduction in the cell size. J Mol Cell Cardiol 2008, 45:106-117.
124. Feng W., Ye F., Xue W., Zhou Z., Kang Y.J. Copper regulation of hypoxia-inducible factor-1 activity. Mol Pharmacol 2009, 75:174-182.
125. Takimoto E., Champion H.C., Li M., Belardi D., Ren S., Rodriguez E.R., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005, 11:214-222.
126. Vidavalur R., Penumathsa S.V., Zhan L., Thirunavukkarasu M., Maulik N. Sildenafil induces angiogenic response in human coronary arteriolar endothelial cells through the expression of thioredoxin, hemeoxygenase and vascular endothelial growth factor. Vascul Pharmacol 2006, 45:91-95.
127. Koneru S., Varma Penumathsa S., Thirunavukkarasu M., Vidavalur R., Zhan L., Singal P.K., et al. Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1. J Cell Mol Med 2008, 12:2651-2664.
128. Zhang M., Takimoto E., Hsu S., Lee D.I., Nagayama T., Danner T., et al. Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. J Am Coll Cardiol 2010, 56:2021-2030.
129. Kinoshita M., Takano H., Takaichi S., Taenaka Y., Nakatani T. Influence of prolonged ventricular assistance on myocardial histopathology in intact heart. Ann Thorac Surg 1996, 61:640-645.
130. Bruckner B.A., Stetson S.J., Perez-Verdia A., Youker K.A., Radovancevic B., Connelly J.H., et al. Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support. J Heart Lung Transplant 2001, 20:457-464.
131. Frazier O.H., Benedict C.R., Radovancevic B., Bick R.J., Capek P., Springer W.E., et al. Improved left ventricular function after chronic left ventricular unloading. Ann Thorac Surg 1996, 62:675-681. discussion 81-2.
132. Petrov G., Regitz-Zagrosek V., Lehmkuhl E., Krabatsch T., Dunkel A., Dandel M., et al. Regression of myocardial hypertrophy after aortic valve replacement: faster in women?. Circulation 2010, 122:S23-S28.
133. Maron B.J., Pelliccia A., Spataro A., Granata M. Reduction in left ventricular wall thickness after deconditioning in highly trained Olympic athletes. Br Heart J 1993, 69:125-128.
134. Pelliccia A., Maron B.J., De Luca R., Di Paolo F.M., Spataro A., Culasso F. Remodeling of left ventricular hypertrophy in elite athletes after long-term deconditioning. Circulation 2002, 105:944-949.
135. Pelliccia A., Maron B.J., Spataro A., Proschan M.A., Spirito P. The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med 1991, 324:295-301.
136. Klues H.G., Schiffers A., Maron B.J. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995, 26:1699-1708.
137. Pelliccia A., Maron B.J., Di Paolo F.M., Biffi A., Quattrini F.M., Pisicchio C., et al. Prevalence and clinical significance of left atrial remodeling in competitive athletes. J Am Coll Cardiol 2005, 46:690-696.
138. Wang L., Seidman J.G., Seidman C.E. Narrative review: harnessing molecular genetics for the diagnosis and management of hypertrophic cardiomyopathy. Ann Intern Med 2010, 152:513-520. [W181].
139. Lewis J.F., Spirito P., Pelliccia A., Maron B.J. Usefulness of Doppler echocardiographic assessment of diastolic filling in distinguishing "athlete's heart" from hypertrophic cardiomyopathy. Br Heart J 1992, 68:296-300.
140. Maron B.J., Spirito P., Green K.J., Wesley Y.E., Bonow R.O., Arce J. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1987, 10:733-742.
141. Derumeaux G., Douillet R., Troniou A., Jamal F., Litzler P.Y., Pontier G., et al. Distinguishing between physiologic hypertrophy in athletes and primary hypertrophic cardiomyopathies. Importance of tissue color Doppler. Arch Mal Coeur Vaiss 1999, 92:201-210.
142. Vinereanu D., Florescu N., Sculthorpe N., Tweddel A.C., Stephens M.R., Fraser A.G. Differentiation between pathologic and physiologic left ventricular hypertrophy by tissue Doppler assessment of long-axis function in patients with hypertrophic cardiomyopathy or systemic hypertension and in athletes. Am J Cardiol 2001, 88:53-58.
143. Sharma S., Elliott P.M., Whyte G., Mahon N., Virdee M.S., Mist B., et al. Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol 2000, 36:864-870.
144. Pelliccia A., Maron B.J., Culasso F., Di Paolo F.M., Spataro A., Biffi A., et al. Clinical significance of abnormal electrocardiographic patterns in trained athletes. Circulation 2000, 102:278-284.
145. Maron B.J., Wolfson J.K., Ciro E., Spirito P. Relation of electrocardiographic abnormalities and patterns of left ventricular hypertrophy identified by 2-dimensional echocardiography in patients with hypertrophic cardiomyopathy. Am J Cardiol 1983, 51:189-194.